Recurrent Childhood Acute Lymphoblastic Leukemia Active Not Recruiting Phase 2 Trials for Mycophenolate mofetil (DB00688)

Back to Recurrent Childhood Acute Lymphoblastic Leukemia

Indication	Status	Phase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)	Active Not Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Treatment	Fludarabine (DB01073) Melphalan (DB01042) Methotrexate (DB00563) Mycophenolate mofetil (DB00688) Tacrolimus (DB00864)
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Treatment	Alemtuzumab (DB00087) Cyclosporine (DB00091) Fludarabine (DB01073) Mycophenolate mofetil (DB00688)
NCT00036738	Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib	Treatment	Cyclosporine (DB00091) Dasatinib (DB01254) Fludarabine (DB01073) Imatinib (DB00619) Mycophenolate mofetil (DB00688) Nilotinib (DB04868)
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Treatment	Fludarabine (DB01073) Mycophenolate mofetil (DB00688) Tacrolimus (DB00864)
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Treatment	Alemtuzumab (DB00087) Cyclosporine (DB00091) Fludarabine (DB01073) Mycophenolate mofetil (DB00688)